Intrahepatic and perihilar cholangiocarcinoma, in particular, grew faster in young patients than in older patients. The report affirms research from other Western countries suggesting such a trend.

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Top 3 High-Momentum Companies Analysts Are Still Bullish On Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom ...

Researchers at Karolinska Institutet in Sweden have analyzed and described in detail the immune cells residing in the human bile duct. The findings may pave the way for new treatment strategies ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

Patients with biliary tract cancer have altered genetic architecture in some immune system receptors. This has been shown by researchers at Karolinska Institutet in Sweden in a new study published in ...

Ziihera is the first dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S., offering a chemotherapy-free treatment option. The FDA's accelerated approval was based on a 52% ...

Biliary tract cancers, including gallbladder cancer, intrahepatic, perihilar, and distal cholangiocarcinomas, although anatomically contiguous, represent a heterogeneous group of cancers with ...

Biliary tract cancers are a diverse set of neoplasms arising from the biliary tract epithelium and include intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal extrahepatic ...

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology show that chemotherapy combining three different types ...